

LESS HARM: INTERNATIONAL DECLARATION FOR A SMOKE-FREE SPAIN

The signatories of this declaration "Less Harm: international declaration for a smoke-free Spain" are public health experts and social-health professionals committed to the fight against smoking, to which doctors and scientists from Spain and 38 other countries have adhered, whose common objective is to reduce the number of smokers.

In Spain, smoking policies have been focused solely on prevention and cessation. However, these measures alone are not enough as they fail to reduce smoking rates or bring them out of stagnation, as the most recent data show. According to the latest EDADES 2019/2020¹ survey, Spain today has the same smoking rates, 32.3% of the population between 15 and 64 years of age, as in 2005, 32.8%, just before the approval of what is known as the first anti-smoking law.

On the other hand, we would like to point out that many countries recognized for their anti-smoking policies, such as the United Kingdom², New Zealand³, Canada⁴, France⁵ and the United States⁶ have responded to the exhaustion of traditional policies with innovative approaches that, on the one hand, take into account the current behaviour of smokers, new forms of consumption and the most advanced science and, on the other, seek to provide pragmatic solutions to the thousands of smokers who are unable or unwilling to quit smoking.

For this reason, we believe that the Spanish authorities have a golden opportunity to apply new measures in the fight against the diseases caused by smoking that are giving significant results in those countries where they are already being applied.

For this reason, and with the aim of contributing to a more effective and rapid reduction in the number of smokers in Spain, we present "Less Harm: International Declaration for a Smoke-free Spain", which includes a series of proposals for a comprehensive approach in the fight against smoking that takes into account the society and the reality of the 21st century.

1- Anti-smoking policies must offer realistic solutions for smokers.

Prevention and cessation have been and are key pillars in the fight against smoking. We agree that these types of actions are fundamental and should continue to be a central support to avoid initiation and achieve smoking cessation. However, cessation and prevention alone are not efficient to reduce the high smoking rates most effectively, as they do not offer a sufficient solution for those people who do not manage to quit smoking through the usual tools. In this sense, it is necessary to incorporate new tools that help modernize policies and minimize the harm that smoking causes to people who smoke.

2- Harm reduction as a complementary tool for advancing the fight against smoking.

There are a lot of smokers in Spain. At least 4.5 million people are unable to quit smoking despite having tried to do so and, according to different studies, only 35% of smokers succeed in quitting with the usual cessation tools, furthermore, relapse rates are very high. In addition, many people who smoke simply do not plan on quitting. For this reason, it is essential to support tools that provide a solution to this problem. In this sense, policies aimed at reducing the harm caused by smoking are an additional route to cessation and prevention in order to achieve this. There is strong scientific evidence¹ and international experience showing that alternative products such as electronic cigarettes or smoke-free tobacco can be part of the solution and not part of the problem in the fight against smoking.

3- Scientific advances, not opinions, must be the cornerstone of the fight against smoking.

As with any issue affecting public health, science should be at the core of any health plan, not preconceived ideas, sensationalism or opinions. In the case of e-cigarettes, heated tobacco, snus and other nicotine products with harm reduction potential, science has already proven in many cases that they are far less toxic than combustible cigarettes and can also help people quit smoking and reduce disease rates in the population, making these devices potentially great tools to help those who do not succeed in quitting, as long as they are properly and specifically regulated to avoid use by never smokers. For example, as a result of this scientific evidence, the UK public health agency recently announced that the UK will be the first country to prescribe medically authorised e-cigarettes for smoking cessation within its National Health Service².

On the other hand, it is essential to listen to all scientific perspectives without exclusion or censorship of any kind in order to optimise the effectiveness of anti-smoking policies. Therefore, the proposed comprehensive tobacco control plan should consider all the available scientific evidence and not just a part of it. Scientific debate, dialogue and not an excluding monologue, is the key for science to move public policies forward. Authorities must listen to the opinion of all professionals and experts who face the daily damage caused by smoking, without persecution or false accusations.

4- More training for health professionals and more information for smokers.

There is a considerable lack of knowledge among the medical community about the potential of harm reduction products in the fight against smoking. Therefore, taking science as the backbone of our proposal, training programmes should be implemented for health professionals (both in the public and private sectors) on the characteristics of these tools and the cases in which they can play a beneficial role. Simultaneously, smokers should have as much information as possible about them. To this end, objective and scientifically validated public information should be provided, always contextualising the fact that these products are not harmless and should only be considered by adult smokers who have tried to quit smoking and have not succeeded. Likewise, efforts must be redoubled to ensure that minors and non-smokers do not start using either traditional tobacco or these new products, without harming adults who need to quit smoking.

5- Harm reduction products need differentiated treatment and regulation.

Harm reduction products such as e-cigarettes and heated tobacco should be regulated as they are not risk-free. However, as they have scientifically proven benefits that can be of significant help to many smokers, they should be clearly regulated differently from traditional combustible cigarettes and should take into account the lower health risk compared to combustible tobacco products. Treating them as the same in terms of public health is a serious mistake, as the message to smokers is that both products have the same impact on their health and therefore removes any incentive to consider switching to less harmful alternatives when other attempts to quit have failed. Making these products equal in terms of access restrictions of any kind for adults, taxation, properties and image to conventional tobacco will only result in thousands of people continuing to smoke and, unfortunately, becoming ill and dying.

6- More restrictions on combustible tobacco products.

Smoking tobacco, which involves inhaling smoke produced by combustion, is the most harmful form of nicotine consumption and the most widespread among the population. It is therefore necessary to strengthen measures against these products, especially the ones most widely consumed by young people, such as roll-your-own tobacco and manufactured cigarettes. The consumption of these products causes the death of 60,000 people a year in Spain.

Therefore, we will support any measure included in the plan that is aimed at increasing taxes and the application of generic packaging for combustion cigarettes, as well as awareness campaigns.

7- Learn from the experience of other countries in the fight against smoking.

Countries such as the UK and New Zealand, among others, are already successfully implementing policies that combine particularly restrictive treatment and regulation of combustible tobacco use with strategies that encourage the use of harm reduction tools for adult smokers. According to the latest Eurobarometer⁸, which also includes the United Kingdom, the smoking rate in this country stands at 12%, five points lower than in 2017. Likewise, in New Zealand, since its Ministry of Health launched its campaign to support the e-cigarette as a tool to quit smoking, the reduction in smoking rates has seen a significant acceleration, reaching a historic decrease of almost 3 points in a single year⁹.

8- Promoting research on these products through public-private sector collaboration.

Scientific advances and technological developments encourage us to believe that the goal of progressively making harm reduction products practically safe for the consumer is achievable. Following the example of other countries, we propose to promote a programme of continuous communication from public authorities to encourage the private sector to devote all possible resources to research into harm reduction products, with the ultimate goal of ending the lethal combustible tobacco use as soon as possible.

With the first Anti-tobacco Law, Spain was at the forefront of the fight against smoking in 2005, becoming an international benchmark. Therefore, more than fifteen years later, Spain has the opportunity to lead this fight again, combining and increasing the effective actions of the past with innovative strategies that are committed to measures adapted to the current reality and that take into account all the new evidence and scientific contributions, as has already been done in nearby countries. Forgetting these strategies, which minimize the damage, will soon make us lead in the rate of diseases caused by smoking at European level. To this end, the proposals contained in this declaration are intended to advance along these lines with the aim of reducing the number of smokers and the impact of diseases caused by smoking in Spain.

NATIONAL SUPPORT TO THIS MANIFESTO

1. **Manuel Linares Abad**, PhD, Professor. Nurse specialist in Obstetrics and Gynecology. Former Dean of the Faculty of Health Sciences University of Jaen Spain.
2. **José M^a García Basterrechea**, MD Associate Professor of Medicine University of Murcia Former head, Addiction and Dual Pathology Unit Reina Sofía Hospital Spain.
3. **Fernando Fernández Bueno**, MD Oncological surgeon at the Hospital Central de la Defensa Gómez Ulla. Professor at the University of Alcalá de Henares Madrid. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. Spain.
4. **Carmen Escrig**, PhD Genetics and Cell Biology. Autonomous University of Madrid. Spain.
5. **Josep María Ramón Torrell**, MD, PhD. Professor of Epidemiology and Public Health University of Barcelona. Head of Clinical Prevention Research Group Bellvitge Biomedical Research Institut. Head of Tobacco Prevention Service Bellvitge Hospital Barcelona. Spain.
6. **Angel González Ureña**, PhD Emeritus Professor of Physical Chemistry. Complutense University of Madrid. Spain.
7. **Carlos Gutiérrez Rodríguez**. MD Specialist in Intensive Care Medicine. Spain.
8. **Miguel de la Guardia** PhD Professor of Analytical Chemistry University of Valencia. Spain.
9. **María del Mar Sangüesa Jareño**, MD Specialist in Intensive Care Medicine. Spain.
10. **Safuan Chaban Navarro**, MD specialist in family and community medicine. Spain.
11. **José David García Muñiz**, MD, PhD Clinical Pharmacology and Internal Medicine Clinical Trials Coordinator, Principal Investigator University Hospital of Ceuta. Spain.
12. **Antonio Sierra**, MD, PhD Professor of Preventive Medicine and Public Health at the University of La Laguna. Former Dean of the Faculty of Medicine of the University of La Laguna. Former General Director of Public Health of the Government of the Canary Islands. Spain.
13. **Guillermo González Balmaseda**. MD Specialist in Psychiatry. Madrid. Spain.
14. **José María Cacigal de Ulloa**. MD Specialist in Stomatology. Spain.

15. **Pablo Hernández Sanz**. MD Specialist in Internal Medicine. 12 de Octubre Hospital. Madrid. Spain.
16. **Manuel Bullón** MD, specialist in Cardiology and Honorary Clinical Professor at the University of Alcalá de Henares, Madrid. Spain.
17. **Luis de Nicolás Navas**. MD. Expert surgeon in Coloproctology. Spain.

INTERNATIONAL SUPPORT TO THIS MANIFESTO

18. **Hugo Caballero Durán**, MD Former president of the Colombian Society of Pneumology. Former Clinical Scientific Director of Marly Clinic. Director of the Pneumology and Respiratory Therapy Service, Marly Clinic Bogotá. Colombia.
19. **Hernán Prat**, MD, Professor at the University of Chile. Former Director of the Cardiovascular Department of the Clinical Hospital of the University of Chile. Former president of the Chilean Society of Hypertension. Chile.
20. **Francisco E. Urrestra**. MD. Medical Director Hospital Clínica Metropolitana. Ibarra. Ecuador.
21. **Diego Verrastro** MD General surgeon specialist in Emergency Medicine. Argentina.
22. **Roberto A Sussman**, PhD. Institute for Nuclear Research, National Autonomous University of Mexico, ICNUNAM. Spokesman Pro-Vapeo Mexico AC. Mexico.
23. **Enrique Teran**, MD, PhD Professor College of Health Sciences - Universidad San Francisco de Quito. Ecuadorian Academy of Medicine. Academy of Science of Ecuador. Ecuador.
24. **Monica Gorgulho**. Clinical Psychologist. Master in Social Psychology. Former President of the Brazilian Harm Reduction Association. Former member of the Executive Board of the International Harm Reduction Association. Former Consultant for the Brazilian Minister of Health on alcohol and other drugs issues. Former representative of the Federal Council of Psychology on the National Council of Drugs. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. Brazil.
25. **Edward Wollants**. MD Specialist in Internal Medicine. Nutritionist and specialist in healthy lifestyle. El Salvador.
26. **Ana María Díaz** PhD in Bioethics. Colombia.
27. **José Manuel Mier Odriozola** M.D. Ph.D. Coordinator. Lung Cancer and Thorax Tumors Clinic. Director Minimal Invasive Thoracic Surgery Institute Angeles Lomas Hospital. México.
28. **Eliana Golberstein-Rubashkin** B.Sc. Pharm, B. Chem Consultant, advisor in health policy and toxicology. National University of Colombia.
29. **Daniel Kleiman Priewer**. MD. Specialist in Sports injuries, Traumatology, Orthopedics, degenerative lesions and articulation Preservation. Santiago. Chile.
30. **Randall Rodríguez Obando**. MD. Specialist in Internal Medicine. Specialist in Harm Reduction applied to patients with HIV. Costa Rica.
31. **Omar Ghiglione** MD. Peripheral Vascular Surgeon. Venezuela, Perú.
32. **Edgar Enrique Caballero Martínez**. Degree in Psychology. Specialist in Distance Education. UNAM. México.
33. **César Paz-y-Miño**, MD, PhD. Medical Geneticist, Medical Director of Genomics Lab. Quito, Ecuador.
34. **Luz Odette Villegas Pichardo** MD. Specialist in Internal Medicine. México.
35. **Christian Heinrich H.** M.D MIPH. Consultant in Public Health policies, México.

36. **María Alejandra Medina García**. Prof. in Public Policies and Master in Sustainability. Harm Reduction Expert. Colombia.
37. **Louise Ross**, smoking cessation expert. Former manager of the Leicester Stop Smoking Service. UK.
38. **Riccardo Polosa**, MD, PhD, FAAAAI Professor of Internal Medicine - Department of Clinical & Experimental Medicine, University of Catania. Director - Institute of Internal Medicine, AOU "Policlinico - V. Emanuele", Catania. Founder - Center of Excellence for the acceleration of HARM Reduction (CoEHAR), University of Catania. Founder and Executive Manager - Center for Tobacco prevention and treatment (CPCT), University of Catania. Honorary Professor of Medicine, University of Southampton (UK). Fellow American Academy of Allergy, Asthma and Immunology. Italy.
39. **Bernhard-Michael Mayer**, PhD Professor of Pharmacology, University Graz, Austria.
40. **Clive D. Bates**, MA, MSc Director, Counterfactual Consulting Former Director, Action on Smoking and Health London. UK.
41. **David T. Swenor** J.D. Chair of the Advisory Board, Centre for Health Law, Policy & Ethics, University of Ottawa. Adjunct Professor, Faculty of Law, University of Ottawa. Global Leadership Council, Boston University School of Public Health. Legal Counsel, Non-Smokers' Rights Association, 1983-2005. International Association on Smoking Control and Harm Reduction (SCOHRE) Board Member. Canada.
42. **Marewa Glover**, Master of Social Science, Diploma in Community Psychology, Ph.D in Behavioural Science. New Zealander of the Year Finalist 2019. Director, Centre of Research Excellence: Indigenous Sovereignty & Smoking, New Zealand. Former Professor of Public Health, Massey University New Zealand. Former Chair of End Smoking NZ. Former Policy Analyst, New Zealand Public Health Commission. New Zealand.
43. **Jacques Le Houezec**, PhD Neuroscientist - Smoking Cessation Specialist - Public Health Consultant - Trainer, Rennes, France.
44. **Gerry Stimson**, Emeritus Professor Imperial College London, UK; Director of Knowledge-Action-Change, London, UK.
45. **John Britton**, Emeritus Professor, University of Nottingham. UK.
46. **Peter Hajek**, Professor Wolfson Institute of Population Health, Queen Mary University of London. UK.
47. **Scott Ballin**, JD Health Policy Consultant. Former Vice President for Public Policy and Legislative Counsel, American Heart Association Former Chair, Coalition on Smoking OR Health. USA.
48. **Martin Juneau** MPs, MD, FRCP(C) Director, Prevention and Cardiac Rehabilitation Montreal Heart Institute. Full Clinical Professor of Medicine Faculty of Medicine University of Montreal. Canada.
49. **Frank Baeyens**, PhD Professor of Psychology Faculty of Psychology and Educational Sciences, KU Leuven. Belgium.
50. **Lion Shahab**, PhD Professor of Health Psychology Department of Behavioural Science and Health University College London. UK.
51. **Lynn T. Kozlowski**, PhD Professor Community Health and Health Behavior. Former Dean School of Public Health and Health Professions University at Buffalo. USA.
52. **Raymond Niaura**, PhD Professor, Social and Behavioral Sciences College of Global Public Health New York University. USA.
53. **Andrzej Sobczak**, PhD Professor Head of Department of General and Inorganic Chemistry Faculty of Pharmaceutical Sciences in Sosnowiec Medical University of Silesia Katowice. Poland

54. **David Nutt** DM FRCP FRCPSych FBPhS FMedSci DLaws. Edmond J. Safra Professor of Neuropsychopharmacology. Director Centre for Psychedelic Research Imperial College London. UK.
55. **Steven A. Schroeder**, MD Professor Emeritus, Department of Medicine University of California, San Francisco. USA.
56. **Kenneth E. Warner**, PhD, Avedis Donabedian Distinguished University Professor Emeritus and Dean Emeritus, University of Michigan School of Public Health. USA.
57. **Ron Christian G. Sison**, MLS(ASCPi), MPH International Medical Laboratory Scientist. Lead Convenor, Harm Reduction Alliance of the Philippines (HARAP). Philippines.
58. **Jasjit S Ahluwalia**, MD, MPH, MS Professor Behavioral and Social Sciences and Professor Medicine Center for Alcohol and Addiction Studies Brown University School of Public Health and Alpert School of Medicine Deputy Director CADRE, a NIH funded Center of Excellence (COBRE), Associate Director (Populations Sciences), Legorreta Cancer Center at Brown. USA.
59. **Colin P Mendelsohn**, MB BS (Hons). Medical practitioner; Tobacco Treatment Specialist; Founding Chairman of the Australian Tobacco Harm Reduction Association. Sydney, Australia.
60. **Rohan Sequeira** Professor, MD, FAGE, FACP (USA), FACLM (USA), FADE (USA), MPCDS (UK), MPCDS (EUR), PhD Endocrine (HARVARD - USA) Consultant Cardio-Metabolic Physician. Specialist in Non-Invasive Cardiology, Diabetes, Endocrinology and Obesity Management. Consultant Physician and Cardiovascular Diabetologist. Mumbai. India.
61. **Alex Wodak** AM, MD, Board Member, Australian Tobacco Harm Reduction Association. Emeritus Consultant, St Vincent's Hospital, Sydney, Australia. Chair, Australia21 Ambassador, Harm Reduction Australia.
62. **Karl E Lund**, PhD Senior Researcher Norwegian Institute of Public Health Oslo. International Association on Smoking Control and Harm Reduction (SCOHRE) Board Vice President. Norway.
63. **Wayne Hall**, Emeritus Professor National Centre for Youth Substance Use Research. The University of Queensland. Australia.
64. **Olivia Maynard**, PhD, Tobacco and Alcohol Research Group, University of Bristol. UK.
65. **Martin J Jarvis**, DSc OBE Emeritus Professor of Health Psychology Department of Behavioural Science and Health University College London. UK.
66. **Lynne Dawkins**. Professor of Nicotine and Tobacco Studies. Centre for Addictive Behaviours Research. Division of Psychology. School of Applied Sciences. London South Bank University. UK.
67. **Kiran Melkote** MD, MBBS, MS (Orthopaedics). Orthopaedic surgeon and former smoker. Member, AHRER (Association for Harm Reduction, Education and Research). India.
68. **Jean-François Etter**, PhD Professor of public health Institute of Global Health, Faculty of Medicine University of Geneva Geneva. Switzerland.
69. **Clifford E. Douglas**, J.D. Director, Tobacco Research Network Adjunct Professor, Department of Health Management and Policy University of Michigan School of Public Health. USA.
70. **Ron Borland** PhD FASSA, Professor of Psychology – Health Behaviour, Melbourne School of Psychological Sciences, The University of Melbourne, Victoria. Australia
71. **Ethan Nadelmann**, JD, PhD Founder & Former Executive Director Drug Policy Alliance. USA.
72. **Robert Beaglehole**, Emeritus Professor University of Auckland, New Zealand and Former Director of Chronic Diseases and Health Promotion, WHO Geneva. New Zealand.

73. **Konstantinos Farsalinos**, MD, MPH Researcher University of Patras, Greece University of West Attica, Greece. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. Greece.
74. **Salvatore Alaimo**, Department of Clinical and Experimental Medicine, University of Catania. Center of Excellence for the acceleration of Harm reduction (coEHAR). Italy.
75. **Carmelina Daniela Anfuso**, Department of Biomedical and Biotechnological Sciences, University of Catania. Center of Excellence for the acceleration of Harm reduction (coEHAR). Italy.
76. **Ignazio Barbagallo**, Department of Drug Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR). Italy.
77. **Francesco Basile**, Department of General Surgery and Medical-Surgical Specialties, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR). Italy.
78. **Sebastiano Battiato**, Department of Mathematics and Computer Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR). Italy.
79. **Brahim Benhamou**, Cadi Ayyad University. Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy. Morocco.
80. **Gaetano Bertino**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy.
81. **Alberto Bianchi**, Department of General Surgery and Medical-Surgical Specialties, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
82. **Antonio G. Biondi**, Department of General Surgery and Medical-Surgical Specialties, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
83. **Maria Luisa Brandi**, National Observatory of Fragility Fractures, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
84. **Emma Cacciola**, Department of Medical, Surgical Sciences and Advanced Technologies, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
85. **Rossella R. Cacciola**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
86. **Bruno Santi Cacopardo**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
87. **Aldo E. Calogero**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
88. **Maria Teresa Cambria**, Department of Biological, Geological and Environmental Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
89. **Davide Campagna**, Department of Emergency Medicine, University of Catania Teaching Hospital Policlinico, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
90. **Filippo Caraci**, Department of Drug Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
91. **Agatino Cariola**, Department of Law Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
92. **Massimo Caruso**, Department of Biomedical and Biotechnological Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy

93. **Pasquale Caponnetto**, Department of Educational Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
94. **Adriana Ciancio**, Department of Law Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
95. **Fabio Cibella**, Institute of Biomedicine and Molecular Immunology, National Research Council, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
96. **Rosita A. Condorelli**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
97. **Maurizio Di Mauro**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
98. **Jennifer Di Piazza**, Hunter Bellevue School of Nursing at Hunter College at the City University of New York, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy. USA.
99. **Adriana Di Stefano**, Department of Law Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
100. **Filippo Drago**, Department of Biomedical and Biotechnological Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
101. **Salvatore Failla**, Department of Chemical Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
102. **Rosario Faraci**, Department of Economics and Business, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
103. **Salvatore Ferlito**, Department of Medical, Surgical Sciences and Advanced Technologies, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
104. **Margherita Ferrante**, Department of Medical, Surgical Sciences and Advanced Technologies, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
105. **Giancarlo A. Ferro**, Department of Law Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
106. **Francesco Frasca**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
107. **Lucia Frittitta**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
108. **Pio M. Furneri**, Department of Biomedical and Biotechnological Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
109. **Antonio Gagliano**, Department of Electrical, Electronics and Computer Engineering, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
110. **Giovanni Gallo**, Department of Mathematics and Computer Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
111. **Fabio Galvano**, Department of Biomedical and Biotechnological Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
112. **Giuseppe Grasso**, Department of Chemical Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
113. **Francesca Guarino**, Department of Biomedical and Biotechnological Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy

114. **Antonino Gulino**, Department of Chemical Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
115. **Emmanuele A. Jannini**, Department of Systems Medicine, University of Rome Tor Vergata, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy.
116. **Sandro La Vignera**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
117. **Giuseppe Lazzarino**, Department of Biomedical and Biotechnological Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
118. **Caterina Ledda**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
119. **Rosalia Maria Leonardi**, Department of General Surgery and Medical-Surgical Specialties, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
120. **Antonio Longo**, Department of General Surgery and Medical-Surgical Specialties, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
121. **Gabriella Lupo**, Department of Biomedical and Biotechnological Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
122. **Mario Malerba**, Department of Translational Biomedicine, University of Eastern Piedmont, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
123. **Luigi Marletta**, Department of Electrical, Electronics and Computer Engineering, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
124. **Costanza Nicolosi**, Department of Law Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
125. **Guido Nicolosi**, Department of Political and Social Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
126. **Francesco Nocera**, Department of Electrical, Electronics and Computer Engineering, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
127. **Renée O'LEARY**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
128. **Gea Oliveri Conti**, Department of Medical, Surgical Sciences and Advanced Technologies, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
129. **Alessandro Ortis**, Department of Mathematics and Computer Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
130. **Giuseppe Palazzo**, Department of General Surgery and Medical-Surgical Specialties, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
131. **Rosalba Parenti**, Department of Biomedical and Biotechnological Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
132. **Eugenio PEDULLÀ**, Department of General Surgery and Medical-Surgical Specialties, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
133. **Alfredo Pulvirenti**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
134. **Francesco Purrello**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy

135. **Francesco Rapisarda**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
136. **Venerando Rapisarda**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
137. **Renata Rizzo**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
138. **Simone Ronsisvalle**, Department of Drug Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
139. **Giuseppe Ronsisvalle**, Department of Drug Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
140. **Martino Ruggieri**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
141. **Maria Santagati**, Department of Biomedical and Biotechnological Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
142. **Cristina Satriano**, Department of Chemical Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
143. **Laura Sciacca**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
144. **Maria Salvina Signorelli**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy.
145. **Lucia Spicuzza**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
146. **Marco Tatullo**, Technologica Research Institute, Marrelli Hospital, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
147. **Daniele Tibullo**, Department of Biomedical and Biotechnological Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
148. **Venera Tomaselli**, Department of Political and Social Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
149. **Paolo Vigneri**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
150. **Vladislav Volarevic**, Faculty of Medical Sciences, University of Kragujevac, Serbia. Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy. Serbia.
151. **Luca Zanolì**, Department of Clinical and Experimental Medicine, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
152. **Agata Zappalà**, Department of Biomedical and Biotechnological Sciences, University of Catania, Center of Excellence for the acceleration of Harm reduction (coEHAR) Italy
153. **Giovanni Li Volti**, MD, PhD, Professor of Biochemistry - Department of Biomedical and Biotechnological Sciences, University of Catania – Director of the Center of Excellence for the acceleration of Harm Reduction (CoEHAR) Italy
154. **Giuseppe Biondi Zoccai**. Associate Professor in Cardiology, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina. International Association on Smoking Control and Harm Reduction (SCOHRE) Board Secretary. Italy.

155. **Ekatherina Charvalos**. Professor, IASO Medical Research & Innovation department & Head of Molecular Biology dpt-INVITROLASBS S.A., Athens, Greece. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. Greece.
156. **Karl Fagerström** Professor Emeritus; President, Fagerstrom Consulting, Sweden. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. Sweden
157. **Ignatios Ikonomidis** MD, PhD, FESC, Professor of Cardiology, Member of EACVI, ex. Nucleus member of ESC WG on Aorta & Peripheral Vascular Diseases, Director of Echocardiography and the Laboratory of Preventive Cardiology, 2nd Cardiology Department, National and Kapodistrian University of Athens, Attikon Hospital, Athens. International Association on Smoking Control and Harm Reduction (SCOHRE) Board President. Greece.
158. **Fares Mili** MD-CTTS, Pulmonologist, Addictologist, Chairman of the Tunisian Society of Tobacology and Addictive Behaviors (STTACA), Tunisia. International Association on Smoking Control and Harm Reduction (SCOHRE) Board Member. Tunisia.
159. **Manuel Pais Clemente** MD, PhD, Retired Full Professor Department of Otorhinolaryngology, Porto University School of Medicine, Vice-President European Medical Association. President World Voice Consortium, Portugal. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. Portugal.
160. **Dimitri Richter** MD, FESC, FAHA, Head of Cardiology Department, Euroclinic Hospital, Athens. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. Greece.
161. **Rajesh Sharan** Professor of Biochemistry, Genetics & Molecular Biology, Radiation and Molecular Biology Unit, Department of Biochemistry, North-Eastern Hill University, Shillong, India. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. India.
162. **Heino Stöver** Social Scientist Director of Institute for Addiction, Research (ISFF), Frankfurt. International Association on Smoking Control and Harm Reduction (SCOHRE) Board Vice President. Germany.
163. **Emil Toldy-Schedel**. Medical Doctor, Cardiologist, General Director of the St. Francis Hospital of Budapest. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. Hungary.
164. **Michael Toumbis** MD, PhD, FCCP, Pneumonologist, President of the Cyprus Institute of Respiratory Diseases, Cyprus. International Association on Smoking Control and Harm Reduction (SCOHRE) Board Treasurer. Cyprus.
165. **Sharifa Ezat Wan Puteh** Professor of Hospital Management and Health Economics; Deputy Dean (Relation & Wealth Creation), Faculty of Medicine, UKM Medical Centre; Previous Head of International Centre for Casemix and Clinical Coding (ITCC), UKM Medical Centre, Malaysia. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. Malaysia.
166. **Giacomo Frati**, Full Professor, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. Italy.
167. **Solomon Rataemane** Africa regional Rep.; World Association for Psychosocial Rehabilitation; HOD Psychiatry UFS 1998-2003; HOD Psychiatry SMU 2003-2019; Chair: Ministerial Advisory Committee

on Mental Health; Chairperson MDB HPCSA 2020-2025. International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. South Africa.

168. Stanimir Hasardzhiev MD. Chairman National Patients Organization, International Association on Smoking Control and Harm Reduction (SCOHRE) Founding member. Bulgaria.

169. Michael Pesko; Associate Professor; Department of Economics; Andrew Young School of Policy Studies; Georgia State University. USA

170. Pavel Bém, Addictology Clinic, Charles University, Prague, former Mayor of Prague. Czech Republic.

BIBLIOGRAPHY

¹ Report 2021 Alcohol, tobacco and illegal drugs in Spain (EDADES). Health Minister Spain.

² Tobacco: preventing uptake, promoting quitting and treating dependence. NICE guideline [NG209]. 30 November 2021

³ Vaping Facts Campaign. New Zealand Health Minister.

⁴ Vaping and quitting smoking. Government of Canada.

⁵ Tabac Info Service. Santé Publique France.

⁶ FDA press release July 2020. FDA Authorizes Marketing of IQOS Tobacco Heating System with 'Reduced Exposure' Information.

⁷ Public Health England Report. Vaping in England: 2022 Evidence Update Summary. 29 September 2022

⁸ Special Eurobarometer 506. Attitudes of Europeans towards tobacco and electronic cigarettes. February 2021

⁹ Smokefree New Zealand. Facts & figures. Information about New Zealand's smoking rates and how they are changing.

ANOTHER INTERESTING REFERENCES:

¹⁰ Beaglehole R, Bonita R. Tobacco control: getting to the finish line. *Lancet*. 2022 May 14;399(10338):1865. doi: 10.1016/S0140-6736(22)00835-2. PMID: 35569463.

¹¹ WHO Framework Convention on Tobacco Control. Article 1d.

¹² L'Etude ECSMOKE. AP-HP. Lancée 2018.

¹³ National Tobacco Reform Initiative. USA.

¹⁴ Balfour DJK, Benowitz NL, Colby SM, Hatsukami DK, Lando HA, Leischow SJ, Lerman C, Mermelstein RJ, Niaura R, Perkins KA, Pomerleau OF, Rigotti NA, Swan GE, Warner KE, West R. Balancing Consideration of the Risks and Benefits of E-Cigarettes. *Am J Public Health*. 2021 Sep;111(9):1661-1672. doi: 10.2105/AJPH.2021.306416. Epub 2021 Aug 19. PMID: 34410826; PMCID: PMC8589069.